Management of depressive symptoms in peri- and postmenopausal women: EMAS position statement.
- Stute P Department of Obstetrics and Gynecology, University Women's Hospital, Bern, Switzerland. Electronic address: petra.stute@insel.ch.
- Spyropoulou A First Department of Psychiatry, Medical School, National and Kapodistrian University of Athens, Greece.
- Karageorgiou V Second Department of Obstetrics and Gynecology, Aretaieio Hospital, Medical School, National and Kapodistrian University of Athens, Greece.
- Cano A Department of Pediatrics, Obstetrics and Gynecology, University of Valencia and INCLIVA, Valencia, Spain.
- Bitzer J Department of Obstetrics and Gynecology, University Hospital, Basel, Switzerland.
- Ceausu I Department of Obstetrics and Gynecology I, "Dr. I. Cantacuzino" Hospital, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
- Chedraui P Instituto de Investigación e Innovación de Salud Integral (ISAIN), Facultad de Ciencias Médicas, Universidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador.
- Durmusoglu F İstanbul Medipol International School of Medicine, Istanbul, Turkey.
- Erkkola R Department of Obstetrics and Gynecology, University Central Hospital, Turku, Finland.
- Goulis DG Unit of Reproductive Endocrinology, First Department of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, Greece.
- Lindén Hirschberg A Department of Women's and Children's Health, Karolinska Institutet and Department of Gynecology and Reproductive Medicine, Karolinska University Hospital, Stockholm, Sweden.
- Kiesel L Department of Gynecology and Obstetrics, University of Münster, Münster, Germany.
- Lopes P Nantes, France Polyclinique de l'Atlantique Saint Herblain. F 44819 St Herblain France, Université de Nantes F 44093 Nantes Cedex, France.
- Pines A Sackler Faculty of Medicine, Tel-Aviv University, Israel.
- Rees M Women's Centre, John Radcliffe Hospital, Oxford OX3 9DU, UK.
- van Trotsenburg M Department of Obstetrics and Gynaecology, University Hospital St. Poelten-Lilienfeld, Austria.
- Zervas I First Department of Psychiatry, Medical School, National and Kapodistrian University of Athens, Greece.
- Lambrinoudaki I Second Department of Obstetrics and Gynecology, Aretaieio Hospital, Medical School, National and Kapodistrian University of Athens, Greece.
- 2019-11-20
Published in:
- Maturitas. - 2020
Depression
EMAS
Early menopause
Menopausal hormone therapy
Menopausal transition
Model of care
Perimenopause
Adult
Aged
Antidepressive Agents
Complementary Therapies
Depression
Depressive Disorder, Major
Europe
Female
Hormones
Humans
Life Style
Menopause
Middle Aged
Perimenopause
Postmenopause
Practice Guidelines as Topic
Societies, Medical
Treatment Outcome
English
INTRODUCTION
Globally, the total number of people with depression exceeds 300 million, and the incidence rate is 70 % greater in women. The perimenopause is considered to be a time of increased risk for the development of depressive symptoms and major depressive episodes.
AIM
The aim of this position statement is to provide a comprehensive model of care for the management of depressive symptoms in perimenopausal and early menopausal women, including diagnosis, treatment and follow-up. The model integrates the care provided by all those involved in the management of mild or moderate depression in midlife women.
MATERIALS AND METHODS
Literature review and consensus of expert opinion.
SUMMARY RECOMMENDATIONS
Awareness of depressive symptoms, early detection, standardized diagnostic procedures, personalized treatment and a suitable follow-up schedule need to be integrated into healthcare systems worldwide. Recommended treatment comprises antidepressants, psychosocial therapies and lifestyle changes. Alternative and complementary therapies, although widely used, may help with depression, but a stronger evidence base is needed. Although not approved for this indication, menopausal hormone therapy may improve depressive symptoms in peri- but not in postmenopausal women, especially in those with vasomotor symptoms.
Globally, the total number of people with depression exceeds 300 million, and the incidence rate is 70 % greater in women. The perimenopause is considered to be a time of increased risk for the development of depressive symptoms and major depressive episodes.
AIM
The aim of this position statement is to provide a comprehensive model of care for the management of depressive symptoms in perimenopausal and early menopausal women, including diagnosis, treatment and follow-up. The model integrates the care provided by all those involved in the management of mild or moderate depression in midlife women.
MATERIALS AND METHODS
Literature review and consensus of expert opinion.
SUMMARY RECOMMENDATIONS
Awareness of depressive symptoms, early detection, standardized diagnostic procedures, personalized treatment and a suitable follow-up schedule need to be integrated into healthcare systems worldwide. Recommended treatment comprises antidepressants, psychosocial therapies and lifestyle changes. Alternative and complementary therapies, although widely used, may help with depression, but a stronger evidence base is needed. Although not approved for this indication, menopausal hormone therapy may improve depressive symptoms in peri- but not in postmenopausal women, especially in those with vasomotor symptoms.
- Language
-
- English
- Open access status
- bronze
- Identifiers
-
- DOI 10.1016/j.maturitas.2019.11.002
- PMID 31740049
- Persistent URL
- https://sonar.ch/global/documents/232414
Statistics
Document views: 34
File downloads:
- Full-text: 0